Climb Bio, Inc.
CLYM
$2.33
-$0.15-6.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 108.40% | 138.60% | 55.84% | -1.56% | -37.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 240.79% | 179.64% | 25.89% | -31.46% | -51.30% |
| Operating Income | -240.79% | -179.64% | -25.89% | 31.46% | 51.30% |
| Income Before Tax | 27.16% | -540.10% | -110.42% | -76.15% | -42.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.16% | -540.10% | -110.42% | -76.15% | -42.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.16% | -540.10% | -110.42% | -76.15% | -42.80% |
| EBIT | -240.79% | -179.64% | -25.89% | 31.46% | 51.30% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 67.47% | -344.98% | -62.22% | -44.56% | -26.56% |
| Normalized Basic EPS | -48.97% | -26.99% | 44.51% | 55.10% | 59.38% |
| EPS Diluted | 67.47% | -344.98% | -62.22% | -44.51% | -26.53% |
| Normalized Diluted EPS | -48.97% | -26.99% | 44.51% | 55.10% | 59.38% |
| Average Basic Shares Outstanding | 136.95% | 110.44% | 75.78% | 42.86% | 6.18% |
| Average Diluted Shares Outstanding | 136.95% | 110.44% | 75.78% | 42.86% | 6.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |